Cargando…
Pharmaceutical Effects of Inhibiting the Soluble Epoxide Hydrolase in Canine Osteoarthritis
Osteoarthritis (OA) is a degenerative joint disease that causes pain and bone deterioration driven by an increase in prostaglandins (PGs) and inflammatory cytokines. Current treatments focus on inhibiting prostaglandin production, a pro-inflammatory lipid metabolite, with NSAID drugs; however, other...
Autores principales: | McReynolds, Cindy B., Hwang, Sung Hee, Yang, Jun, Wan, Debin, Wagner, Karen, Morisseau, Christophe, Li, Dongyang, Schmidt, William K., Hammock, Bruce D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554663/ https://www.ncbi.nlm.nih.gov/pubmed/31214021 http://dx.doi.org/10.3389/fphar.2019.00533 |
Ejemplares similares
-
In vitro and in vivo Metabolism of a Potent Inhibitor of Soluble Epoxide Hydrolase, 1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea
por: Wan, Debin, et al.
Publicado: (2019) -
Soluble Epoxide Hydrolase Deletion Limits High-Fat Diet-Induced Inflammation
por: Wagner, Karen M., et al.
Publicado: (2021) -
Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty
Acid Amide Hydrolase Inhibitors
por: Kodani, Sean D., et al.
Publicado: (2018) -
Editorial: Clinical Paths for Soluble Epoxide Hydrolase Inhibitors
por: Imig, John D., et al.
Publicado: (2020) -
Inhibition of the Soluble Epoxide Hydrolase as an Analgesic Strategy: A Review of Preclinical Evidence
por: Wang, Yuxin, et al.
Publicado: (2021)